[A case of unresectable pancreatic cancer that responded to UFT chemotherapy].
A 77-year-old patient with an unresectable pancreatic cancer was treated with a combination chemotherapy of UFT (600 mg/day, p.o.) and Lentinan (2 mg/week, i.v.). After three and a half months, a partial response (PR) was achieved, based on the criteria of Koyama, Saito, et al. The findings of the follow up CT scans suggested that 600 mg/day of UFT, rather than 300 mg/day, was effective as a chemotherapeutic agent. Although transient thrombocytopenia (62,000/mm2) and eruption were observed during this therapy, no serious side effects were experienced. After eighteen months of this chemotherapy, the patient has not succumbed and manifests a good quality of life.
Sato
Y
Y
Dept. of Int. Med., Japanese Red Cross Nagoya 1st Hospital.
Sakai
T
T
Okada
T
T
Sasano
Y
Y
Ando
T
T
Haruta
J
J
Kanayama
K
K
Kuwahara
Y
Y
Tachino
H
H
Tahara
H
H
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D007912:Lentinan / Q000008:administration & dosage; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D005641:Tegafur; D007912:Lentinan; D014498:Uracil